T2 Biosystems

T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish.
Company Growth (employees)
Lexington, US
Size (employees)
168 (est)
T2 Biosystems was founded in 2006 and is headquartered in Lexington, US

Key People at T2 Biosystems

Sarah Kalil

Sarah Kalil

Chief Operating Officer
Michael Cima

Michael Cima

Co-Founder and Director
Tom Lowery

Tom Lowery

Vice President of Diagnostics Research & Development
Rahul Dhanda

Rahul Dhanda

Vice President of Global Support Services Marketing

T2 Biosystems Office Locations

T2 Biosystems has offices in Lexington and Wilmington
Lexington, US (HQ)
101 Hartwell Ave
Wilmington, US
231 Andover St

T2 Biosystems Data and Metrics

T2 Biosystems Financial Metrics

T2 Biosystems's revenue was reported to be $4.1 m in FY, 2016 which is a 45% increase from the previous period.
$, USD

Revenue (FY, 2016)

4.1 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(54.8 m)

EBIT (FY, 2016)

(50.9 m)

Market capitalization (23-Jun-2017)

118.4 m

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

73.5 m
T2 Biosystems's current market capitalization is $118.4 m.
$, USDFY, 2014FY, 2015FY, 2016


119 k2.8 m4.1 m

Revenue growth, %


R&D expense

19.8 m25.4 m24 m

General and administrative expense

11 m19.1 m24.1 m

Operating expense total

30.8 m46.2 m55 m


(30.7 m)(43.4 m)(50.9 m)

EBIT margin, %


Interest expense

(721 k)(2 m)(4.1 m)

Net Income

(31.4 m)(45.3 m)(54.8 m)
$, USDFY, 2014FY, 2015FY, 2016


73.8 m73.7 m73.5 m

Accounts Receivable

201 k369 k327 k


115 k683 k820 k

Current Assets

75.3 m75.6 m75.4 m


2.8 m10.7 m13.6 m

Total Assets

79.1 m86.9 m89.6 m

Accounts Payable

735 k1.2 m962 k

Current Liabilities

5.2 m12.3 m9.9 m

Additional Paid-in Capital

156.6 m195.8 m243 m

Retained Earnings

(103.6 m)(148.9 m)(203.7 m)

Total Equity

53 m46.9 m39.3 m

Financial Leverage

1.5 x1.9 x2.3 x
$, USDFY, 2014FY, 2015FY, 2016

Net Income

(31.4 m)(45.3 m)(54.8 m)

Depreciation and Amortization

691 k1.5 m2.3 m

Accounts Receivable

(201 k)(168 k)42 k


(1.2 m)(568 k)

Accounts Payable

(208 k)177 k(61 k)

Cash From Operating Activities

43.7 m(187 k)(46.4 m)

Purchases of PP&E

(2.1 m)(8 m)(5.5 m)

Cash From Investing Activities

(2.1 m)(7.9 m)(5.5 m)

Cash From Financing Activities

73.9 m45.2 m51.8 m

Interest Paid

515 k1.5 m2.7 m
Y, 2016

Financial Leverage

2.3 x

T2 Biosystems Operating Metrics

T2 Biosystems's Facilities was reported to be 2 in FY, 2016. T2 Biosystems's Patent Applications was reported to be 50 in FY, 2016
FY, 2016



Patents Issued


Patent Applications


T2 Biosystems Market Value History

T2 Biosystems Online and Social Media Presence

T2 Biosystems Company Life and Culture

You may also be interested in